Cartesian Therapeutics (RNAC) Accumulated Depreciation (2015 - 2016)
Cartesian Therapeutics' (RNAC) quarterly Accumulated Depreciation came in at $3.3 million in Q2 2016, up 13.32% on a QoQ basis from $2.9 million in Q4 2015.
Cartesian Therapeutics (RNAC) Accumulated Depreciation (2015 - 2016) Analysis & Trends
Cartesian Therapeutics (RNAC) has 2 years of Accumulated Depreciation data on file, last reported at $3.3 million in Q2 2016.
- On a quarterly basis, Accumulated Depreciation changed N/A year-over-year to $3.3 million in Q2 2016; TTM through Jun 2016 was $3.3 million, a N/A change from a year earlier, with the FY2015 full-year figure at $2.9 million, changed N/A from the prior year.
- Accumulated Depreciation for Q2 2016 stood at $3.3 million, up from $2.9 million in the prior quarter.
- Over the last five years, Accumulated Depreciation for RNAC reached as high as $3.3 million in Q2 2016 and fell as low as $2.9 million in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Cartesian Therapeutics | 210.28 Mn | 210.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | 3.32 Mn |
| Dec 31, 2015 | 2.93 Mn |